NFKB1 and colitis: Since ILK mediates activation of the TLR4/NF-κB/TNF-α signaling pathway by LPS (a TLR4 agonist) in colitis (Ahmed et al., 2014), it is possible that ILK could have an impact on regulating the activities of different TLRs in cancer.